The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Ixazomib plus chemotherapy for AML & ALL
Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA, discusses results of recent investigations of the addition of ixazomib to chemotherapy in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Good tolerability and promising efficacy results support the use of ixazomib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
